AtriCure (ATRC): BTIG Reiterates Buy Rating and $54 PT | ATRC St

robot
Abstract generation in progress

BTIG has reiterated a Buy rating for AtriCure (ATRC) with a price target of $54. This decision aligns with a positive trend of analyst ratings for ATRC, including recent Buy or Overweight ratings from Needham, JP Morgan, and Canaccord Genuity. Analysts collectively project an average target price of $53.38, implying a 61.89% upside from the current price, further supported by GuruFocus’ estimated GF Value suggesting a 45.34% upside.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)